Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up study of oral brigimadlin in patients with solid tumors
MOH_2025-03-18_013941Phase 2Not yet recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of brigimadlin in Nonhematologic neoplasms (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Treatment-emergent adverse events. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
brigimadlin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2025-03-18_013941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-03-18_013941.